IBSACOL FOR IBS IBSACOL contains Meracol, a trademarked and patented plant based fatty acid ester. Mode of Action Published third party research demonstrates the relationship between inflammation and IBS, and the connection between low levels of the anti-inflammatory cytokine IL 10 with IBS and IBD.[i] [i]References: -
Chadwick et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology; 122(7): 2078-80, 2002C [abstract] -
S Schreiber. Interleukin-10 in the intestine (commentary). GUT;41:274-275, 1997 [abstract] -
RC Spiller. Neuropathology of IBS? Gastroenterology: 2144-7, 2002 [abstract] - Gonsalkorale WM, Perrey C, Pravica V, Whorwell PJ, Hutchinson IV. Interleukin 10 genotypes in irritable bowel syndrome: evidence for an inflammatory component?. Gut;52(1):91-3, 2003 [abstract]
- Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell;75(2):263-74, 1993 [abstract]
- S Nikolaus, J Bauditz, P Gionchetti, C Witt, H Lochs, S Schreibera. Increased secretion of pro-inflammatory cytokines by circulating polymorphonuclear neutrophils and regulation by interleukin 10 during intestinal inflammation. GUT 42:470-476, 1998 [abstract]
- L Steidler. New Cytokine treatment for inflammatory bowel disease. Science 289: 1352-4, 2000
- K. Asadullah, W. Sterry and H. D. Volk. Interleukin-10 Therapy—Review of a New Approach. Pharmacol Rev 55:241-269, 2003 [abstract]
[ii] Immune effects of Meracol: Pilot data analysis – Professor Jeff Keelan, Liggins Institute, University of Auckland, New Zealand
___________________________________________________________ Dr. T.D. Meakin B.Sc. M.D. FRNZCGP*
Auckland, New Zealand I was co-investigator in a double-blinded trial using Meracol (the active ingredient in IBSACOL) at Wellington Hospital, New Zealand in 1998-99. During the trial, a dosage of 26 capsules of Meracol was taken daily, after a four-week period this was reduced to 16 capsules per day. During the trial, side effects were monitored as instructed by SCOTT. The two side effects that were recorded in the active treatment group were constipation (2/27) and headache (3/27). These were transient and, with adequate hydration, resolved spontaneously. Bloods were taken at Week 1, at Week 3 and at Week 5 Included in this profile were:
| Hb | Cr | | MCV | Urea | | wbc | Albumin | | Neutrophils | Protein | | Lymphocytes | ALP | | Monocytes | ALT | | Eosinophils | GGT | | Basophils | AST | | Na | Bilirubin | | K | Fasting lipids | From these tests, one can conclude that Meracol has a good safety profile as all of these blood tests remained unchanged during the trial with the 27 active patients treated with Meracol. The only exception was a slight increase in HDL or good cholesterol levels. No adverse reactions or drug interactions were reported. Overall I was impressed with the limited side-effect profile that Meracol produced, even at a relatively high dose.
Yours sincerely
Tim Meakin B.Sc. M.D. FRNZCGP Dr. T.D. Meakin B.Sc. M.D. FRNZCGP*
Auckland, New Zealand Dear Ibsacol Customer, I was involved in further clinical trials during May 2002. These investigations involved the active ingredient of IBSACOL and were conducted at the Liggins Research Institute in Auckland New Zealand. This trial required the monitoring of blood and the recording of adverse reaction by patients. No negative effects were recorded on the blood profiles and the patient involved reported no adverse side effects. I have been impressed with the results of these studies and conclude that IBSACOL appears to be a safe and well-tolerated therapy.
Yours sincerely
Tim Meakin B.Sc. M.D. FRNZCGP ___________________________________________________________
* After observing the effects of IBSACOL in patients with IBS Dr. Meakin has become a shareholder and Medical Director of Meracol Corporation. |
